Group 1 - Class Action Attorney Juan Monteverde's firm, Monteverde & Associates PC, is investigating Core Scientific, Inc. related to its sale to CoreWeave, Inc. [1] - Upon completion of the proposed transaction, each outstanding share of Core Scientific common stock will be converted into the right to receive 0.1235 shares of CoreWeave Class A common stock [1] - Core Scientific shareholders will own less than 10% of the combined company after the transaction [1] Group 2 - Monteverde & Associates PC is recognized as a Top 50 Firm in the 2024 ISS Securities Class Action Services Report and has recovered millions for shareholders [1] - The firm is headquartered in the Empire State Building, New York City, and has a successful track record in trial and appellate courts, including the U.S. Supreme Court [2]

Core Insights - Class Action Attorney Juan Monteverde's firm, Monteverde & Associates PC, is investigating PB Bankshares Inc. in relation to its proposed sale to Norwood Financial Corp. [1] - The transaction offers PB Bankshares' shareholders the choice of receiving either 0.7850 shares of Norwood common stock or $19.75 in cash for each common share they own, with a proration clause ensuring that 80% of the total consideration is paid in Norwood stock [1] Company Overview - Monteverde & Associates PC is recognized as a Top 50 Firm in the 2024 ISS Securities Class Action Services Report and has a successful track record in recovering millions for shareholders [1] - The firm operates from the Empire State Building in New York City and specializes in class action securities litigation [2] Transaction Details - The proposed sale of PB Bankshares to Norwood Financial Corp. includes an option for shareholders to elect their preferred form of compensation, either stock or cash [1] - The proration mechanism is designed to ensure that a significant majority (80%) of the transaction consideration is distributed in the form of Norwood common stock [1]

NOW: 🇺🇸 "[Ripple was] the first leading U.S. company to be sued by the SEC," @bgarlinghouse says before the Senate."Fortunately, after four years of a hard fought legal battle, we prevailed." https://t.co/xGocFmZWNp ...

Core Viewpoint - A securities class action lawsuit has been filed against Sarepta Therapeutics, Inc. for allegedly misleading investors regarding the safety and efficacy of its gene therapy treatment, ELEVIDYS, during the specified Class Period from June 22, 2023, to June 24, 2025 [1][2]. Group 1: Allegations Against Sarepta - The lawsuit claims that Sarepta made false or misleading statements about the safety risks associated with its gene therapy treatment, ELEVIDYS [2]. - It is alleged that the trial protocols for ELEVIDYS failed to identify severe side effects, which could lead to regulatory scrutiny and halt recruitment and dosing in ongoing trials [2]. - The severity of adverse events from ELEVIDYS treatment is said to have been downplayed, resulting in materially misleading statements from the company [2]. Group 2: Lead Plaintiff Process - Investors in Sarepta have until August 25, 2025, to apply to be appointed as lead plaintiffs, representing the interests of the class in the litigation [3]. - The lead plaintiff is typically the investor or small group of investors with the largest financial stake in the case [3]. - Participation as a lead plaintiff does not affect the ability of other investors to share in any potential recovery from the lawsuit [3]. Group 3: Firm Information - Kessler Topaz Meltzer & Check, LLP is the law firm handling the class action and has a reputation for prosecuting class actions and recovering significant amounts for victims of corporate misconduct [4]. - The firm encourages affected investors to reach out for more information regarding the lawsuit [4].

Core Points - A shareholder class action lawsuit has been filed against Red Cat Holdings, Inc. alleging that the company made materially false and misleading statements regarding its production capacity and the value of the SRR Contract [1] - The lawsuit claims that the defendants overstated the production capacity of the Salt Lake City Facility and the overall value of the SRR Contract, leading to misleading public statements [1] Legal Information - Shareholders who purchased Red Cat shares between March 18, 2022, and January 15, 2025, and suffered significant losses are encouraged to discuss their legal rights with the law firm Holzer & Holzer [2] - The deadline to request to be appointed as lead plaintiff in the case is July 22, 2025 [3]

Group 1 - The Rosen Law Firm is reminding purchasers of Compass Diversified Holdings securities from March 1, 2023, to May 7, 2025, about the lead plaintiff deadline for a securities class action on July 8, 2025 [1] - Investors who purchased Compass securities may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2] - A class action lawsuit has already been filed, and interested parties can join by contacting the Rosen Law Firm [3][6] Group 2 - The lawsuit alleges that during the class period, Compass' subsidiary, Lugano Holdings, Inc., had unrecorded financing arrangements and irregularities in its financial statements, which affected the reliability of Compass' overall financial statements [5] - The lawsuit claims that Compass failed to maintain adequate internal controls related to its financial statements, leading to materially false and misleading public statements [5]

ATLANTA, Ga., July 08, 2025 (GLOBE NEWSWIRE) -- A shareholder class action lawsuit has been filed against iRobot Corporation (“iRobot” or the “Company”) (NASDAQ: IRBT). The lawsuit alleges that Defendants made materially false and/or misleading statements and/or failed to disclose material adverse information about iRobot’s business, operations, and prospects, including allegations that: (i) iRobot overstated the extent to which the Restructuring Plan would help the Company maintain stability after the term ...

Core Viewpoint - Krispy Kreme, Inc. is facing a class action lawsuit due to alleged misleading statements regarding its partnership with McDonald's and declining product demand, which has resulted in significant financial losses for investors [1][4][5]. Group 1: Company Overview - Krispy Kreme manufactures and sells doughnuts and has been expanding its partnership with McDonald's since October 2022, starting with a small-scale test in Louisville, Kentucky [3]. - The partnership was announced to expand nationwide in the second half of 2024 [3]. Group 2: Allegations and Financial Impact - The lawsuit claims that during the class period, Krispy Kreme failed to disclose a significant decline in demand for its products at McDonald's locations, which negatively impacted average sales [4]. - It is alleged that the partnership with McDonald's was not profitable and posed risks to its continuation, leading to a suspension of further expansion into new locations [4]. - On May 8, 2025, Krispy Kreme reported a net revenue of $375.2 million, a 15.3% year-over-year decline, and a net loss of $33.4 million, compared to a $6.7 million loss the previous year [5]. - Following the financial report and reassessment of the rollout schedule with McDonald's, Krispy Kreme's stock price fell nearly 25% [5].

Core Viewpoint - A class action has been filed against Sarepta Therapeutics, Inc. for allegedly misleading investors regarding the safety of its gene therapy drug, ELEVIDYS, during the period from June 22, 2023, to June 24, 2025 [1][2]. Allegations - The complaint alleges that Sarepta failed to disclose significant safety risks associated with ELEVIDYS, including the inability of trial protocols to detect severe side effects and the potential for adverse events to halt recruitment and dosing in clinical trials [2]. - Specific incidents include a patient death reported on March 18, 2025, leading to a stock price drop of $27.81 per share (27.44%) to close at $73.54 [3]. - A second patient death due to acute liver failure was disclosed on June 15, 2025, resulting in a further stock price decline of $15.24 per share (42.12%) to close at $20.91 [3]. - Following an FDA investigation announcement regarding acute liver failure risks on June 24, 2025, Sarepta's stock fell by $1.52 per share (8.01%) to close at $17.46 [4]. Class Action Participation - Shareholders interested in participating as lead plaintiffs must file a motion by August 25, 2025, but can remain absent class members without taking action [5].

SAN DIEGO, July 07, 2025 (GLOBE NEWSWIRE) -- Robbins LLP reminds stockholders that a class action was filed on behalf of investors who purchased or otherwise acquired Petco Health and Wellness Company, Inc. (NASDAQ: WOOF) securities between January 14, 2021 and June 5, 2025. Petco is a specialty retailer that offers a variety of pet products, services, and solutions. For more information, submit a form, email attorney Aaron Dumas, Jr., or give us a call at (800) 350-6003. The Allegations: Robbins LLP is Inv ...